^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GC101 TIL

    i
    Other names: tumor infiltrating lymphocytes, GC101 TIL, autologous tumor infiltrating lymphocytes
    Associations

    News

    Trials
    Company:
    Gencells Therapeutics
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    2years
    Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen. (PubMed, J Immunother Cancer)
    Omitting high dose of IL-2, she received intravenous dose of cyclophosphamide (20 mg/kg) for 3 days, approximately 48 hours before receiving the intravenous infusion of TILs. These results illustrated the potential value of modified lymphodepletion, followed by TILs for the treatment of patients with cervical cancer with local recurrence. Trial registration number, NCT04766320.
    Journal • Tumor-Infiltrating Lymphocyte
    |
    IL2 (Interleukin 2)
    |
    PD-1 expression
    |
    cyclophosphamide • GC101 TIL